The Claim

In Pkd1RC/RC mice, treatment with fenofibrate, a PPARα agonist, is associated with reduced bile duct cyst number, decreased cyst proliferation, and diminished liver inflammation and fibrosis, suggesting that metabolic modulation via PPARα activation attenuates polycystic liver disease in this animal model.

Source: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Fenofibrate, a drug that changes how the liver processes energy, seems to help reduce liver cysts and damage in a type of mouse with a genetic liver disease.

See the scientific wording

In Pkd1RC/RC mice, fenofibrate treatment is associated with reduced bile duct cyst number, cyst proliferation, and liver inflammation and fibrosis, indicating that metabolic modulation with a PPARα agonist also attenuates polycystic liver disease in this animal model.

What the research says

1 study

  1. Study: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

    The study gave fenofibrate to mice with a disease similar to human polycystic liver disease and found fewer liver cysts and less damage, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.